AbbVie Risankizumab Shows Improvements in 2 Phase 3 Induction Studies in Crohn's

 AbbVie (NYSE: ABBV) today announced positive results from two Phase 3 induction studies, ADVANCE and MOTIVATE, showing both doses of risankizumab (600 mg and 1200 mg) met both primary endpoints of clinical remission and endoscopic response at week 12 in adult patients with moderate to severe Crohn's disease.1,2 The ADVANCE study enrolled patients who had an inadequate response or were intolerant to conventional and/or biologic therapy.1 The MOTIVATE study evaluated patients who had responded inadequately or were intolerant to biologic therapy.2

https://www.streetinsider.com/Corporate+News/AbbVie+%28ABBV%29+Risankizumab+Demonstrates+Significant+Improvements+in+Clinical+Remission+and+Endoscopic+Response+in+Two+Phase+3+Induction+Studies+in+Patients+with+Crohns+Disease/17795520.html